BioLife Solutions, Inc. logo

BioLife Solutions, Inc.

BLFS

NASDAQHealthcareMedical - Instruments & Supplies

Previous close

$37.10

+$0.13 · +0.35%

Aug 21, 4:00 PM ET

BLFS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

69

Undervalued

Momentum

60

Neutral

Sentiment

34

Bearish

Risk resilience

53

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

BioLife Solutions, Inc. (BLFS) operates as a global provider of specialized bioproduction tools and services, primarily catering to the cell and gene therapy industry. Its market reach extends across the United States, Canada, Europe, the Middle East, Africa, and other international regions. The company's offerings are essential for various stages of biologic-based therapy development, spanning from foundational and applied research to large-scale commercial manufacturing. Key products include proprietary biopreservation media, such as HypoThermosol FRS and CryoStor, which are engineered to minimize delayed cell damage and death typically associated with preservation. Complementing these are the ThawSTAR products, an automated line of devices for thawing vials and cryobags, designed to precisely manage the heat and timing for optimal biologic material thawing. BLFS also provides innovative cloud-connected evo shipping containers for the passive storage and secure transport of temperature-sensitive biologics and pharmaceuticals. Additionally, its comprehensive range encompasses liquid nitrogen laboratory freezers, various cryogenic equipment and accessories, and specialized storage services for biological and pharmaceutical products. Products are distributed both directly to customers and through a network of third-party distributors. Established in 1987, BioLife Solutions, Inc. maintains its headquarters in Bothell, Washington.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
US
CEO
Roderick de Greef
Listed since
Nov 22, 1989
Employees
155

Market position

Day range

Current $37.10

52-week range

Current $37.10

Open
$36.58
Previous close
$36.97
Volume
750.37K
0.83× average
Average volume
908.86K
Average daily volume
Market cap
1.81B USD
Beta
1.9
Market reference 1
50-day average
$30.3132
+22.39% above average
200-day average
$24.9187
+48.88% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.14B USD
P/E (TTM)
35.88×
P/B (TTM)
4.32×
P/S (TTM)
17.63×
EV / EBITDA
316.01×
Earnings yield
-1.05%
Free cash flow yield
0.04%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
64.48%
Operating margin
7.25%
Net margin
49.06%
Return on equity
-3.26%
Return on assets
-2.99%
Return on invested capital
-0.28%

Financial health

Debt / equity
0.04×
Current ratio
5.94×
Altman Z-score
39.24
Piotroski F-score
5 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends90%-9%-109%-208%Gross margin, FY2021: 30.25%Gross margin, FY2022: 61.53%Gross margin, FY2023: 60.75%Gross margin, FY2024: 65.25%Gross margin, FY2025: 64.56%Operating margin, FY2021: -25.72%Operating margin, FY2022: -7.77%Operating margin, FY2023: -104.13%Operating margin, FY2024: -8.67%Operating margin, FY2025: -1.12%Net margin, FY2021: -7.48%Net margin, FY2022: -183.38%Net margin, FY2023: -97.66%Net margin, FY2024: -24.54%Net margin, FY2025: -12.61%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 30.25%. Gross margin FY2022 61.53%. Gross margin FY2023 60.75%. Gross margin FY2024 65.25%. Gross margin FY2025 64.56%. Operating margin FY2021 -25.72%. Operating margin FY2022 -7.77%. Operating margin FY2023 -104.13%. Operating margin FY2024 -8.67%. Operating margin FY2025 -1.12%. Net margin FY2021 -7.48%. Net margin FY2022 -183.38%. Net margin FY2023 -97.66%. Net margin FY2024 -24.54%. Net margin FY2025 -12.61%.

Income trends

Revenue

96.21M USD+16.97%

Operating income

−1.08M USD+84.84%

Net income

−12.13M USD+39.90%
Income trends across reported periods145.05M USD41.47M USD−62.12M USD−165.7M USDRevenue, FY2021: 119.16M USDRevenue, FY2022: 76.24M USDRevenue, FY2023: 68.02M USDRevenue, FY2024: 82.25M USDRevenue, FY2025: 96.21M USDOperating income, FY2021: −30.65M USDOperating income, FY2022: −5.92M USDOperating income, FY2023: −70.83M USDOperating income, FY2024: −7.13M USDOperating income, FY2025: −1.08M USDNet income, FY2021: −8.91M USDNet income, FY2022: −139.81M USDNet income, FY2023: −66.43M USDNet income, FY2024: −20.18M USDNet income, FY2025: −12.13M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 119.16M USD. Revenue FY2022 76.24M USD. Revenue FY2023 68.02M USD. Revenue FY2024 82.25M USD. Revenue FY2025 96.21M USD. Operating income FY2021 −30.65M USD. Operating income FY2022 −5.92M USD. Operating income FY2023 −70.83M USD. Operating income FY2024 −7.13M USD. Operating income FY2025 −1.08M USD. Net income FY2021 −8.91M USD. Net income FY2022 −139.81M USD. Net income FY2023 −66.43M USD. Net income FY2024 −20.18M USD. Net income FY2025 −12.13M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue96.21M USD82.25M USD68.02M USD76.24M USD119.16M USD
Cost of goods sold34.1M USD28.58M USD26.7M USD29.33M USD83.11M USD
Gross profit62.12M USD53.67M USD41.32M USD46.91M USD36.05M USD
Research and development7.57M USD7.91M USD18.8M USD14.8M USD11.82M USD
Selling, general, and administrative55.37M USD50.15M USD54.17M USD44.93M USD48.09M USD
Operating expenses62.94M USD60.8M USD58.52M USD52.83M USD59.5M USD
Interest expense2.71M USD719K USD1.81M USD687K USD485K USD
Depreciation and amortization4.69M USD8.66M USD12.3M USD7.58M USD12.87M USD
Operating income−1.08M USD−7.13M USD−70.83M USD−5.92M USD−30.65M USD
Net income−12.13M USD−20.18M USD−66.43M USD−139.81M USD−8.91M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
82%
9 beats, 2 misses, 0 met estimates
Average EPS surprise
+379.25%
11 comparable reports
Latest EPS result
0.91
Estimate 0.03 · Beat by 2812.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.010.530.05-0.43Q1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 3, 2025: actual -0.01, estimate -0.06, surprise +83.33%, Beat. Q2 2025, reported May 8, 2025: actual 0.04, estimate -0.03, surprise +233.33%, Beat. Q3 2025, reported Aug 7, 2025: actual -0.33, estimate -0.02, surprise -1550.00%, Miss. Q4 2025, reported Nov 6, 2025: actual 0.04, estimate 0.002, surprise +1900.00%, Beat. Q1 2026, reported Feb 26, 2026: actual 0.04, estimate -0.02, surprise +300.00%, Beat. Q2 2026, reported May 7, 2026: actual 0.04, estimate 0.01, surprise +300.00%, Beat. Q3 2026, reported Aug 6, 2026: actual 0.91, estimate 0.031, surprise +2812.00%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 0.01, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates30.34M27.06M23.78M20.51MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 3, 2025: actual 22.71M USD, estimate 21.67M USD, surprise +4.79%, Beat. Q2 2025, reported May 8, 2025: actual 23.94M USD, estimate 22.22M USD, surprise +7.74%, Beat. Q3 2025, reported Aug 7, 2025: actual 25.42M USD, estimate 23.71M USD, surprise +7.21%, Beat. Q4 2025, reported Nov 6, 2025: actual 28.1M USD, estimate 25.69M USD, surprise +9.38%, Beat. Q1 2026, reported Feb 26, 2026: actual 24.76M USD, estimate 24.08M USD, surprise +2.85%, Beat. Q2 2026, reported May 7, 2026: actual 27.5M USD, estimate 25.66M USD, surprise +7.15%, Beat. Q3 2026, reported Aug 6, 2026: actual 28.47M USD, estimate 27.8M USD, surprise +2.41%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 29.17M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$31.00

16.44% downside
Past 12 months12-month forecastHigh $31.00Average $31.00Low $31.00

Rating distribution

18 ratings
Strong buy00%
Buy1267%
Hold633%
Sell00%
Strong sell00%

Recent analyst actions

9 institutions
Stephens & Co.downgradeOverweightEqual Weight
JefferiesdowngradeBuyHold
Lake StreetdowngradeBuyHold
KeybancmaintainOverweight

BLFS peers

ETFs holding BLFS

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research BLFS

research.disclaimer